The patients enrolled on this new study will serve as an appropriate comparison group consisting of patients with the diagnosis of germ cell testicular cancer who were cured with surgical resection and did not receive cisplatin-based chemotherapy with a group of patients from another study who did receive cisplatin-based chemotherapy.

Primary Objective

To compare the prevalence of ototoxicity and neurotoxicity in GCT cancer survivors who only had surgery to a similar population from The Platinum Study (RSRB45410/1305011509) who received cisplatin-based combination chemotherapy.

Secondary Objective

To compare the prevalence of obesity, hypertension, and use of antidepressants/anxiolytics in GCT cancer survivors who only had surgery to a similar population from The Platinum Study who received cisplatin-based combination chemotherapy.

Inclusion Criteria:

• Diagnosis or confirmation of diagnosis of a histologically or serologically confirmed testicular germ cell tumor (GCT) or GCT at another anatomic location
• Age at GCT diagnosis: 55 years of age or younger
• Males, 18 years of age or older at time of study consent
• Subject is able to provide consent
• Subject is able to speak and read English
• Treatment consisted of surgery only (i.e., orchiectomy and/or retroperitoneal lymph node dissection [RPLND]) for either initial testicular germ cell tumor (GCT) or subsequent testicular cancer
• Subject completed surgery > 1 year ago
• Subject is currently undergoing active follow-up at IU
• Subject did not require any subsequent chemotherapy, salvage chemotherapy treatment or bone marrow transplant.
• Subject had no prior chemotherapy of any kind

Exclusion Criteria:

• Patients with prior chemotherapy (whether for GCT or any other cancer)

Male patients with testicular germ cell tumor diagnosis at the age of 18-55 who were treated with surgery only and not chemotherapy.